Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 7Pheochromocytoma 6Thyroid Carcinoma, Anaplastic 5Pituitary Neoplasms 5Paraganglioma 5Insulinoma 5Somatostatinoma 4Vipoma 3Serotonin Syndrome 3Lung Neoplasms 3Glucagonoma 3Gastro-enteropancreatic neuroendocrine tumor 3Gastrinoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Carcinoma, Medullary 3Carcinoma, Islet Cell 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Unknown Primary 2Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Growth Hormone-Secreting Pituitary Adenoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

veliparib 1Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Non functioning pancreatic endocrine tumor × Endocrine × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡